Complement C5a

Complement C5a 詳細

英語名Complement C5a市販薬剤の数1
治験薬の数2ターゲットの別称C5a Complement,Complement 5a,Complement Component 5a
研究&開発段階Approved
英語名Complement C5a
ターゲットの別称C5a Complement,Complement 5a,Complement Component 5a
市販薬剤の数1
治験薬の数2
研究&開発段階Approved

Complement C5a 製品リスト

  • 属性

    Protein (6)Kits (2)

  • 製品ライブラリ

    オンライン (8)

  • Human (4)Mouse (2)Cynomolgus (2)

  • タグ

    Tag Free (2)His Tag (3)Fc Tag (1)- (2)

  • マーカー

    Unconjugated (6)- (2)

Complement C5aバックグランド

Complement component C5a (C5a) is a protein fragment generated upon cleavage of complement component C5. It is a potent chemotactic factor for human peripheral blood neutrophils and monocytes and is believed to play an important role in a number of inflammatory conditions. The major functions of C5a are as follows: C5a is an anaphylatoxin, causing the release of histamine from mast cells; C5a is an effective leukocyte chemoattractant, promoting the accumulation of white blood cells, especially neutrophil granulocytes, at sites of complement activation; C5a activates white blood cells by increasing integrin avidity and upregulating the lipoxygenase pathway for arachidonic acid metabolism; C5a is a powerful inflammatory mediator and appears to be a key factor in the pathogenesis of many inflammatory diseases involving the complement system; and C5a modulates the balance between activating and inhibitory IgG Fc receptors on leukocytes, a mechanism that may enhance autoimmune responses under pathological conditions.

Complement C5a分子の別称

C5a,Complement Component 5a

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
BDB-001BDB-001; BDB001; BDB 001; BDB-1Phase 3 ClinicalStaidson(Beijing) Biopharmaceuticals Co LtdAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Hidradenitis Suppurativa; Vasculitis
詳細
STSA-1002STSA-1002; STSA1002Phase 3 ClinicalStaidson(Beijing) Biopharmaceuticals Co LtdAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
VilobelimabIFX-1; CaCP-29ApprovedInflarx NvGohibicEURespiratory Distress Syndrome, AdultInflarx Nv, Inflarx Gmbh2025-01-13Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Carcinoma, Squamous Cell; Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Granulomatosis with Polyangiitis; Hidradenitis Suppurativa; Microscopic Polyangiitis; Pyoderma Gangrenosum; Respiratory Distress Syndrome, Adult; Sepsis; Shock, Septic; Systemic Inflammatory Response Syndrome
詳細

レビュー

  • 1***52019-09-26
    0評価
    I have ordered a lot of proteins from Acro. This one especially impressed me. Not only that they generously sent me the trial for my pre-experiment, but also they would develop different species of proteins that I need, which saved me a lot of time. Most importantly, ACRO not only does binding experiments, but also tests related functional assay. They even share them with customers. It is quite comprehensive. May all proteins come from you, ACRO.
  • 詳細
  • 製品リスト
  • 市販薬剤に関する情報
  • レビュー
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8